Onasemnogene Abeparvovec (Zolgensma): Market Analysis, Patent Landscape, And Competitive Outlook, 2025 - 2033

Report Overview

Onasemnogene abeparvovec, marketed as Zolgensma, is a one-time gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients with bi-allelic mutations in the SMN1 gene. Developed by Novartis Gene Therapies, it delivers a functional copy of the SMN1 gene using an adeno-associated virus serotype 9 (AAV9) vector, enabling sustained production of the survival motor neuron (SMN) protein, which is critical for motor neuron function. This approach targets the underlying genetic cause of SMA rather than managing symptoms, differentiating it from traditional therapies.

The therapy is approved for use in patients under 2 years of age, including pre-symptomatic infants, based on clinical evidence showing significant improvements in motor milestones, survival, ventilator-free time, and developmental outcomes when administered early. Zolgensma is administered as a single-dose intravenous infusion, offering a one-time curative strategy compared with chronic treatments.

Key Report Deliverables

• Analyze the Onasemnogene abeparvovec (Zolgensma) landscape, detailing the current market size, growth drivers, and key industry trends, particularly in light of the upcoming patent expiration and the impact of biosimilars entering the market.

• Forecast Market Growth, projecting future trends for the Onasemnogene abeparvovec (Zolgensma), highlighting emerging opportunities within the biosimilar space, and assessing potential risks to growth as competition increases following patent expiry.

• Identify Regulatory and Market Barriers, providing insights into regulatory and market barriers that could impact future market expansion and product development, with a specific focus on the challenges biosimilars may face in gaining approval and market access.

• Concurrent Competitive Landscape, identifying key players in the Onasemnogene abeparvovec (Zolgensma), including both originator and biosimilar manufacturers. Examine their strategic moves, partnerships, and distribution of market share to understand competitive positioning and potential shifts as biosimilars are introduced.

• Regulatory Barriers, identifying key regulatory challenges related to the entry of Ibalizumab (Trogarzo) biosimilars, including approval processes and market access restrictions, and assessing their potential impact on the speed and scope of market expansion.

• Strategic Implications, evaluating strategic moves for manufacturer and its competitors to maintain leadership in the Aflibercept market. This includes exploring innovation, differentiation, potential patient support programs, and geographic expansion strategies.

Patent Landscape and Exclusivity Outlook

The patent landscape for onasemnogene abeparvovec is broad and layered, encompassing composition of matter claims on the AAV9 vector SMN1 gene construct, manufacturing processes, and specific therapeutic uses. Core patents originate from early 2010s filings related to AAV9 mediated SMN1 gene delivery and gene therapy methods for spinal muscular atrophy, with subsequent families covering optimised vector design, promoters and large-scale production technologies. Public patent analytics indicate more than one core family with differentiated geographic coverage and staggered expiry dates. For high value markets, several key patents are expected to expire in the early to mid-2030s, with further secondary filings potentially extending protection around process improvements and refinements in vector design. The complexity and novelty of the platform, combined with regulatory data protection, creates a high barrier to exact biosimilar or biobetter entry.

Zolgensma benefits from multiple layers of exclusivity, including patent protection, orphan drug exclusivity and data exclusivity in the United States and Europe. In the US, orphan designation and biologic status confer defined periods of market exclusivity in addition to patent life, while in the European Union conditional marketing authorisation and orphan designation provide parallel regulatory protection. Given expected expiries of major patents in the early to mid-2030s, meaningful generic or biosimilar style competition is unlikely before that timeframe in key markets, particularly given scientific and regulatory challenges in demonstrating equivalence for complex gene therapies. Over the medium term, competitive pressure is more likely to arise from alternative mechanisms for spinal muscular atrophy such as antisense oligonucleotides and small molecule SMN2 splicing modifiers, rather than direct copies of onasemnogene abeparvovec.

Current Market Scenarios

Zolgensma reshaped the SMA treatment market on launch through its one-time curative intent profile and very high upfront price, positioning it as a premium option for newly diagnosed infants. Over time, however, sales growth has moderated as the initial pool of prevalent, treatment naive patients have been largely addressed and as payers have tightened access criteria, often restricting use to younger patients with confirmed biallelic SMN1 mutations and limited SMN2 copy number. Real world data and longer term follow up from pivotal trials have reinforced durability of motor function gains in many treated children, supporting continued clinical adoption within defined eligible populations.

The competitive environment has intensified with the maturation of nusinersen and risdiplam, which offer chronic maintenance options and in the case of risdiplam a convenient oral route of administration. Market shares across the three leading agents have converged, with treatment choice increasingly driven by age at diagnosis, disease severity, family preference, and national reimbursement frameworks rather than by clinical efficacy alone. Recent reports indicate that Zolgensma revenues have plateaued and, in some regions, declined, reflecting the shrinking incident patient pool, scrutiny of cost effectiveness, and broader access to alternative therapies. Nevertheless, Zolgensma remains a cornerstone option in many SMA care pathways and continues to anchor discussions on value-based pricing for gene therapies.

Market Dynamics

“Expanding Adoption of Gene Therapy in Rare Neuromuscular Disorders”

The primary driver for onasemnogene abeparvovec is the growing clinical and regulatory acceptance of gene therapy as a transformative treatment modality for severe pediatric neuromuscular disorders such as spinal muscular atrophy. Increasing newborn screening rates are identifying patients earlier, enabling timely intervention that maximizes the therapy’s potential to preserve motor function and reduce long-term disability. As healthcare systems gain experience with one-time genetic treatments, confidence in the durability and real-world benefits of Zolgensma continues to improve. This shift is reinforced by accumulating clinical evidence demonstrating sustained motor milestone achievement, improved survival, and delayed disease progression in eligible infants.

A second driver stems from the strong alignment between Zolgensma’s therapeutic profile and payer priorities focused on long-term value creation. Although the therapy carries a high upfront cost, modeling consistently shows meaningful offsets in lifetime care expenditures by reducing hospitalizations, ventilation requirements, and chronic supportive care needs associated with untreated or undertreated SMA. Health technology assessments increasingly acknowledge the economic rationality of early gene therapy intervention in a disease with predictable progression and high societal burden. This economic defensibility supports broader reimbursement adoption, particularly in markets equipped with structured rare-disease funding mechanisms.

“Narrow Eligibility and Access Restrictions Limiting Patient Volume”

A major restraint is the limited eligible population defined by strict regulatory and payer criteria. Many reimbursement systems restrict access to infants below a specified age threshold or those with certain SMN2 copy numbers, reducing real-world uptake. These restrictions reflect clinical concerns about administering high-dose systemic gene therapy in older or more advanced patients and financial pressures tied to the therapy’s cost. As a result, the number of newly diagnosed patients meeting full eligibility has declined, particularly in regions with established newborn screening, where the backlog of untreated prevalent patients has already been largely addressed.

Another restraint arises from the logistical, clinical, and operational requirements associated with gene therapy delivery. Zolgensma administration demands specialized centers, trained personnel, careful liver function monitoring, and adherence to pre- and post-treatment corticosteroid protocols. These demands create bottlenecks in markets with limited pediatric neuromuscular infrastructure. Additionally, long-term safety considerations, including risks of hepatotoxicity and rare but serious adverse events, maintain cautious prescribing behavior among clinicians. Together, these clinical and operational barriers slow wider adoption and limit penetration beyond highly specialized pediatric centers.

“Strengthening Pipeline Synergies and Earlier Diagnosis Pathways”

A significant opportunity lies in the continued global expansion of newborn screening programs for SMA, which materially increases the number of patients identified at an early, pre-symptomatic stage where Zolgensma demonstrates the greatest benefit. As more countries implement mandatory SMA screening, incident patient detection will improve, creating sustained annual demand. Parallel advancements in genetic counseling and diagnostic turnaround times further support timely referral to treatment centers. These system-level improvements align with payer interest in early intervention and contribute to more predictable treatment flows, stabilizing long-term market outlooks for gene therapy interventions like Zolgensma.

There is also considerable opportunity in leveraging manufacturing scale, improved vector production technologies, and expanded treatment infrastructure to establish Zolgensma as the foundation of gene therapy readiness within healthcare systems. As hospitals invest in gene therapy-certified centers, Zolgensma serves as an anchor therapy that validates operational frameworks for future AAV-based treatments. Additionally, advancements in dosing strategies, safety monitoring, and patient-selection algorithms may broaden the addressable population over time, particularly in regions that gradually relax restrictive reimbursement criteria. These dynamics create a pathway for stronger market resilience as the broader gene therapy ecosystem matures.

“Increasing Integration of Gene Therapy into Standard Rare-Disease Care Pathways, Expansion of Newborn Screening as a Catalyst for Earlier SMA Diagnosis, Intensifying Competition from Alternative SMA Therapeutics and Modalities”

• Increasing Integration of Gene Therapy into Standard Rare-Disease Care Pathways

The growing normalization of gene therapy in neuromuscular care is reshaping clinical practice, with Zolgensma serving as one of the first large-scale real-world examples of a one-time disease-modifying treatment. As clinicians gain familiarity with patient selection, safety monitoring, and long-term follow-up processes, gene therapy is becoming operationally integrated into pediatric neurology centers. This shift reduces earlier hesitancy associated with novel modalities and strengthens institutional readiness for future genetic medicines. Such system-level maturity increases efficiency and enhances confidence among providers, improving the likelihood that eligible infants receive timely referrals and treatment initiation.

• Expansion of Newborn Screening as a Catalyst for Earlier SMA Diagnosis

The rapid global expansion of newborn screening for spinal muscular atrophy is transforming the treatment landscape by enabling diagnosis at pre-symptomatic stages, where therapeutic impact is maximized. More countries are incorporating SMA testing into national screening panels, resulting in earlier identification and intervention. This trend supports stronger clinical outcomes, reduces long-term disease burden, and aligns directly with Zolgensma's highest-value use cases. Earlier diagnosis also reduces variability in clinical presentation, creating more uniform treatment pathways and stabilizing annual patient volumes in markets with mature screening infrastructure.

• Intensifying Competition from Alternative SMA Therapeutics and Modalities

The SMA therapeutic landscape is becoming more diversified, creating a competitive environment that influences treatment patterns and market share dynamics. Chronic maintenance therapies such as nusinersen and risdiplam offer established safety profiles and dosing flexibility, making them attractive alternatives in certain patient groups. As long-term data accumulates for these therapies, physicians now tailor treatment decisions based on clinical phenotype, caregiver preference, and healthcare-system capabilities, rather than relying solely on the curative promise of gene therapy. This competitive maturity encourages shared decision-making and drives more nuanced positioning across therapeutic options.

Overview of Alternative Therapeutics

Alternative therapeutics to onasemnogene abeparvovec include established and emerging disease-modifying treatments targeting different mechanisms within the spinal muscular atrophy pathway. The principal alternatives are nusinersen and risdiplam, which remain widely used due to broader age eligibility, predictable safety profiles, and flexible dosing schedules. Nusinersen, an intrathecal antisense oligonucleotide, enhances SMN2 gene splicing to increase SMN protein production and is administered repeatedly over a patient’s lifetime. Risdiplam, an orally administered SMN2 splicing modifier, offers a convenient, non-invasive option suitable for both pediatric and adult patients. These therapeutics provide ongoing maintenance rather than one-time correction, making them appropriate in scenarios where gene therapy is contraindicated or inaccessible.

Broader treatment alternatives encompass supportive respiratory management, nutritional interventions, orthopedic care, and rehabilitative strategies that help maintain function but do not alter disease biology. Additional investigational approaches include next-generation gene therapies, neuroprotective compounds, and combination regimens designed to optimize motor neuron survival. As clinical practice evolves, therapeutic selection increases depend on patient age, disease severity, SMN2 copy number, caregiver preference, and long-term safety considerations. This diversified ecosystem ensures that treatment pathways remain flexible and personalized, even as gene therapy establishes itself as a cornerstone option for early diagnosed infants.

Competitive Landscape

The competitive environment for onasemnogene abeparvovec is defined by the presence of two major disease-modifying alternatives, a growing pipeline of next-generation SMA therapies, and evolving reimbursement frameworks that influence treatment choice. Zolgensma maintains a differentiated position as the only one-time gene replacement therapy targeting the root cause of SMA through SMN1 gene delivery. This positioning gives it a strategic advantage in early-diagnosed infants, particularly in markets with mature newborn screening systems. However, competition is strong across broader age groups, where chronic therapies remain dominant due to wider eligibility, long-term safety familiarity, and established clinical pathways.

Nusinersen and risdiplam serve as the primary concurrent competitors, collectively covering the majority of patients who fall outside Zolgensma’s age or genetic eligibility criteria. Nusinersen offers sustained efficacy for a wide patient population but requires ongoing intrathecal administration, while risdiplam provides an oral option with broad accessibility and manageable long-term dosing. These products create meaningful therapeutic choice and reduce Zolgensma’s penetration in older or more clinically complex patients. Additional competitive pressure is emerging from pipeline gene therapies and SMN-enhancing candidates under development, as well as improvements in chronic supportive care that enhance survival and function. Overall, the market is transitioning toward a diversified, phenotype-driven landscape where no single therapy dominates all SMA segments.

Regional Analysis

North America Onasemnogene abeparvovec (Zolgensma) Market

North America remains the most established market for Zolgensma, driven by early regulatory approval, widespread newborn screening, and strong clinical infrastructure for gene therapy administration. The United States maintains the highest treatment penetration due to mature reimbursement models, dedicated rare-disease funding programs, and a large network of certified treatment centers. Access criteria can still be restrictive, with payers often limiting therapy to infants below a defined age or with specific SMN2 copy numbers, but overall adoption remains strong. Canada shows similar clinical uptake, though provincial reimbursement variability creates uneven access. The region continues to lead in real-world evidence generation supporting long-term therapy value.

Europe Onasemnogene abeparvovec (Zolgensma) Market

Europe represents a diverse but strategically significant market characterized by highly structured health technology assessment processes and country-specific reimbursement frameworks. Zolgensma is approved broadly, but access is more tightly controlled than in North America, with many countries enforcing rigid eligibility criteria, age limits, or caps on SMN2 copy numbers. Negotiated outcomes-based payment models have helped expand uptake in key markets such as Germany, Italy, and France. The rapid expansion of SMA newborn screening across the region supports earlier diagnosis and steady incident patient volume. However, treatment decision-making often balances Zolgensma against established alternatives like nusinersen and risdiplam, resulting in a more competitive environment.

Asia Pacific Onasemnogene abeparvovec (Zolgensma) Market

Asia Pacific is a rapidly evolving market where access is improving but remains uneven due to economic disparities, limited specialist centers, and variable reimbursement coverage. High-income markets such as Japan, Australia, and South Korea have established approval and coverage pathways, supported by strong clinical capacity for advanced therapies. Middle-income countries show growing clinical interest but face constraints related to affordability and healthcare infrastructure. Newborn screening rates are expanding but remain inconsistent across the region, delaying early diagnosis and limiting eligibility for gene therapy. Despite these barriers, long-term demand is expected to rise as more governments prioritize rare-disease treatment access.

Latin America Onasemnogene abeparvovec (Zolgensma) Market

Latin America presents significant market potential but faces complex reimbursement and infrastructure challenges. Brazil and Argentina are among the most advanced markets, with selective public or private sector funding available for high-cost SMA therapies. Access is often determined on a case-by-case basis, influenced by judicial rulings, private insurance policies, or special access programs. Limited newborn screening coverage and delayed diagnosis reduce the number of infants who meet eligibility for early gene therapy administration. Economic instability and currency fluctuations also impact procurement and pricing negotiations. Despite these hurdles, broader regional investment in rare-disease care is gradually improving treatment availability.

Middle East and Africa Onasemnogene abeparvovec (Zolgensma) Market

The Middle East and Africa region shows the widest disparities in access. High-income Gulf states, including the UAE, Saudi Arabia, and Qatar, have established reimbursement mechanisms that enable relatively consistent access to Zolgensma through national or employer-funded insurance schemes. These markets also possess the specialized pediatric neurology infrastructure required for gene therapy administration. In contrast, much of Africa remains constrained by limited diagnostic capabilities, inconsistent newborn screening, and restricted funding for high-cost rare-disease therapies. Access is typically limited to private-sector pathways or international assistance programs. Long-term growth potential depends heavily on improvements in healthcare financing and infrastructure development.

Analyst Perspective

Zolgensma continues to occupy a strategically important position in the global SMA market, but its long-term trajectory reflects the realities of a maturing rare-disease therapy landscape. As newborn screening becomes increasingly standardized, the therapy is securing a stable incident patient base, reinforcing its value in early-diagnosed infants where clinical outcomes are strongest. However, market expansion is constrained by narrow eligibility criteria, high upfront cost, and payer scrutiny, which limits penetration beyond the earliest stages of disease. Competitive pressure from nusinersen and risdiplam is also reshaping prescribing patterns, particularly in older or more complex patients for whom ongoing maintenance therapy is perceived as safer and more manageable.

From a commercial lens, Zolgensma’s outlook is defined by the balance between its undeniable therapeutic impact and the structural barriers inherent to high-cost gene therapy delivery. While real-world evidence continues to validate durability and functional benefits, future growth will rely on continued improvements in reimbursement models, scaling of gene-therapy infrastructure, and broader adoption of newborn screening in emerging markets. The therapy remains a landmark product that sets expectations for value, access, and outcomes in the gene-therapy category, but sustaining momentum will require targeted strategic execution as the competitive and regulatory environment becomes more sophisticated.

Case Study (Recent Engagement): Keytruda Patent-Cliff & Price- Erosion Impact Model

PROJECT OBJECTIVE

To evaluate the potential revenue, price, and patient access implications of Keytruda’s 2028 patent cliff, incorporating biosimilar entry dynamics, country-specific adoption curves, and Merck’s lifecycle defense strategies (remarkably the subcutaneous formulation). The goal was to provide the client with a transparent, scenario-based model to anticipate outcomes and inform strategy

GVR SOLUTION

• Built a bottom-up commodity-flow and analogue-based model, anchored on Merck’s $29.5B Keytruda sales in 2024.

• Integrated jurisdictional LOE timelines (EU mid-2028, U.S. 2028-2029 pending litigation outcomes).

• Modeled biosimilar adoption S-curves calibrated to oncology antibody analogues (EU faster via tenders, U.S. slower via contracting).

• Applied price-erosion benchmarks (EU -15-30% Yr-1, deepening to -45-60% by Yr-3; U.S. -10-25% net decline over same horizon).

• Layered lifecycle defenses (SC uptake assumptions of 25-40% of innovator units, combo refresh, contracting) to quantify buffers.

• Delivered outputs as a dynamic Excel scenario tool and a management-ready PPT deck with revenue bridges, sensitivity tornadoes, and SC migration visuals.

IMPACT FOR CLIENT

• Enabled the client to quantify downside vs. defense-optimized revenue trajectories:

  • Base case: 30-40% global revenue decline by Year-3 post-LOE.

  • Downside: 45-55% decline in tender-heavy markets.

  • Defense-optimized: Contained erosion to ~-20-25% with strong SC adoption.

• Gave the client a clear view of which markets drive early erosion (EU) and where strategic contracting or SC migration can preserve share (U.S.).

• Equipped decision-makers with a playbook of watch-points (tender concentration, litigation outcomes, SC IP coverage, combo pipeline) to guide commercial strategy.

• Provided a transparent methodology that could be presented to boards/investors with evidence-backed assumptions

WHY THIS MATTERS

• Keytruda is the world’s best-selling cancer drug, representing nearly one-third of Merck’s revenue.

• Patent expiry will reshape both Merck’s earnings profile and global oncology access dynamics.

• Payers and governments stand to benefit from biosimilar entry through lower costs, but manufacturers need to manage cliff risk while capturing upside from lifecycle innovations.

• Understanding how quickly revenues erode and how patient access expands post-biosimilar is critical for:

  • Biopharma companies (strategic planning, pipeline prioritization).

  • Investors (valuing Merck’s cash flows beyond 2028).

  • Payers and policymakers (budgeting for oncology drug spend).

A robust patent cliff model helps clients navigate the dual challenge of price erosion and patient expansion, ensuring strategies are grounded in real-world benchmarks.